



KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH

(A unit of Kovai Medical Center and Hospital Limited)

Coimbatore, Tamil Nadu

Department of Pharmacology

New Drug Update

(New Drugs and Available Drugs with New Formulation)

New drugs approved by FDA

- 1. Mavacamten**
- 2. Trientine tetrahydrochloride**
- 3. Oteseconazole**
- 4. Benzoyl peroxide**
- 5. Bevacizumab-maly**
- 6. Alpelisib**
- 7. Dexmedetomidine**

New drugs approved by CDSCO

- 8. Nirmatrelvir bulk and Nirmatrelvir + Ritonavir**
- 9. Sugammadex sodium**
- 10. Finerenone**
- 11. Liothyronine Sodium**

"Discovery is seeing what everyone else has seen, and thinking what nobody else has thought"



Series - 34
May 2022

1. Mavacamten	2. Trientine tetrahydrochloride	3. Oteseconazole
<p>Date of Approval: April 28, 2022</p> <p>Mechanism of action: Inhibits excessive myosin-actin cross-bridge formation</p> <p>Indication: Class II-III obstructive hypertrophic cardiomyopathy</p> <p>Dosage Formulation: Capsule</p>	<p>Date of Approval: April 28, 2022</p> <p>Mechanism of action: Copper chelation</p> <p>Indication: Stable Wilson's disease who are de-coppered and tolerant to penicillamine</p> <p>Dosage Formulation: Tablet</p>	<p>Date of Approval: April 23, 2021</p> <p>Mechanism of action: Selective inhibitor of fungal CYP51 & inhibits the formation of ergosterol</p> <p>Indication: Recurrent vulvovaginal candidiasis</p> <p>Dosage Formulation: Capsule</p>

4. Benzoyl peroxide	5. Bevacizumab-maly	6. Alpelisib
<p>Date of Approval: April 22, 2022</p> <p>Mechanism of action: Oxidizing agent</p> <p>Indication: Inflammatory lesions of rosacea in adults</p> <p>Dosage Formulation: Cream</p>	<p>Date of Approval: April 13, 2022</p> <p>Mechanism of action: Vascular endothelial growth factor inhibitor</p> <p>Indication: Metastatic colorectal cancer; non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; cervical cancer; epithelial ovarian, fallopian tube, primary peritoneal cancer</p> <p>Dosage Formulation: Intravenous Injection</p>	<p>Date of Approval: April 5, 2022</p> <p>Mechanism of action: Selectively inhibits PIK3 in the PI3K/AKT kinase</p> <p>Indication: Adult and paediatric patients 2 years of age and older with PIK3CA-Related Overgrowth Spectrum</p> <p>Dosage Formulation: Tablet</p>

7. Dexmedetomidine	8. Nirmatrelvir Bulk and Nirmatrelvir + Ritonavir	9. Sugammadex sodium
<p>Date of Approval: April 5, 2022</p> <p>Mechanism of action: Alpha2-adrenergic receptor agonist</p> <p>Indication: Agitation associated with schizophrenia or bipolar I or II disorder in adults</p> <p>Dosage Formulation: Sublingual Film</p>	<p>Date of Approval: April 21, 2022</p> <p>Mechanism of action: Protease inhibition</p> <p>Indication: Adult patients with COVID19, with SpO2 >93%</p> <p>Dosage Formulation: Tablet and Combipack Tablets</p>	<p>Date of Approval: April 18, 2022</p> <p>Mechanism of action: Binds to rocuronium or vecuronium & reversing their neuromuscular blocking action</p> <p>Indication: Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adult</p> <p>Dosage Formulation: Bolus Intravenous Injection</p>

10. Finerenone	11. Liothyronine Sodium
<p>Date of Approval: April 11, 2022</p> <p>Mechanism of action: Selective antagonist of mineralocorticoid receptor</p> <p>Indication: To reduce the risk of sustained eGFR decline in chronic kidney disease associated with type 2 Diabetes</p> <p>Dosage Formulation: Film coated tablet</p>	<p>Date of Approval: April 4, 2022</p> <p>Mechanism of action: Hormone replacement</p> <p>Indication: Severe Hypothyroidism</p> <p>Dosage Formulation: Tablet</p>